Tern appoints Rob Stevens as adviser on shareholder relations

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the Board of Tern has appointed Robert (Rob) Stevens as an adviser to the Company on shareholder relations.

Mr Stevens, a private shareholder in the Company, brings experience of the UK small-cap investment community and will provide the Board with strategic advice and guidance, in conjunction with the Company’s other advisers, on investor communications and shareholder sentiment, to allow the Company to remain closely attuned to market views as it pursues its long-term value creation strategy.

The Board will continue to evaluate the appropriateness of appointing additional advisers in due course, as part of its ongoing commitment to enhancing shareholder engagement and value creation.

Conditional Grant of Options

Mr Stevens has conditionally been granted 1,000,000 options over ordinary shares of 0.02p each in the Company.

The grant and any exercise of the Conditional Options will be conditional on the Company obtaining the requisite authorities to satisfy the issue and allotment of any new Ordinary Shares resulting from the future potential exercise of the Conditional Options, which will involve the passing of a resolution at a future general meeting of shareholders.

Subject to the satisfaction of the Conditions, the Conditional Options will vest in equal monthly amounts over three years from the date of the satisfaction of the Conditions, and will be exercisable for a period of 10 years from the date of vesting at a price of 1.70p per Ordinary Share, being approximately double the mid-market closing price of the Ordinary Shares on 29 August 2025, the last practical date prior to this announcement.

Following the satisfaction of the Conditions, the total number of options outstanding over Ordinary Shares in Tern Plc will be 11,500,000.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Pharma faces a strategic turning point in AI adoption

AI in pharma is moving from operational support to strategic driver as companies prioritise messaging that delivers measurable prescriber impact.

Tern Plc updates position in Talking Medicines with new convertible loan notes

Tern Plc has received about £230,000 in new unsecured convertible loan notes from Talking Medicines after cancelling around £180,000 of short term loans provided over 2024 and 2025.

The real problem holding back connected vehicle programmes

Vehicle identity is fast becoming a core infrastructure challenge, and a new bottleneck for OEMs aiming to scale software-defined platforms.

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Search

Search